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Implantation and the Fetal Health
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Andrea Pirkovic and Andjela Perovic
Abstract
Implantation is one of the crucial periods in human reproduction. Increasing body 
of evidence suggests that the improper (dysfunctional) implantation and the forma-
tion of the placenta can endanger life and health of both the fetus and the mother, 
during prenatal life and decades after delivery. The idea of the inverted pyramid of 
prenatal care has emerged in the recent years, as the early detection and prevention of 
health disorders of the fetus are specially focusing on the first trimester. By applying 
this principle, disorders in the perinatal period could be prevented or treated with 
better outcome. The changes that lead to the deficient implantation should be sought 
in the preimplantation period, in relation between the embryo and the endometrium. 
It is possible that the time is approaching when the disorders of the pregnancy caused 
by dysfunctional implantation would be the indication for the application of a natural 
IVF (without ovarian stimulation) with the use of new biotechnological achieve-
ments. For better results of the perinatal medicine, it is necessary to apply earlier (in 
the preconception and preimplantation periods) the therapy based on the subcellular 
and genetic level by applying the latest biotechnological procedures.
Keywords: implantation, fetal health, pregnancy complications
1. Introduction
Most of the fetal and maternal complications become apparent with advancing 
gestation. However, since very important complications that occur later in preg-
nancy can be predicted in the first trimester, the focus has been set on the evalua-
tions in early pregnancy, thus inverting the pyramid of prenatal care. Although vast 
majority of early screening tests have been developed and employed, the outcome 
of pregnancies with the major obstetric syndromes still fails to be significantly 
improved. The changes etiologically and pathophysiologically associated with 
disturbed placentation and responsible for the perinatal mortality and morbidity 
should be sought even earlier, in the preimplantation period, in relation between 
the embryo and the endometrium.
2. Early pregnancy screening tests and algorithms
The idea of inverted pyramid of prenatal care has emerged for the purpose of 
prediction and prevention and then early detection and treatment of health disor-
ders of the fetus. By applying this principle, a number of disorders could be pre-
vented or treated with better outcome: fetal aneuploidy and anomalies, miscarriage, 
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stillbirth, preterm delivery, preterm premature rupture of membranes, preeclamp-
sia, and intrauterine growth restriction [1].
In recent years, screening for aneuploidies during the first trimester has reached 
effectiveness of over 90% in identifying the most common aneuploidies by a 
combination of maternal age, fetal nuchal translucency, as well as analysis of free 
beta-hCG and pregnancy-associated plasma protein A (PAPP-A) [2]. Effectiveness 
of screening for potential aneuploidies was further augmented with the introduc-
tion of the noninvasive prenatal testing using maternal plasma cell-free (cf) DNA, 
as a secondary test in those patients already regarded as being at high risk. The 
detection rate of major aneuploidies with this test is up to 99. 3%, with false positive 
rate of 0. 11% [3].
The development of sonography and MRI diagnostics has led to a growing num-
ber of early detected anomalies. A large number of these anomalies can be detected 
already at 11–14 weeks, while a number can only be found at a later gestation [4]. 
The prenatal detection rate for the major anomalies is around 68% (varying from 33 
to 96%) [5, 6].
First trimester screening often focuses on fetal aneuploidy and major structural 
anomalies. However, certain maternal characteristics, such as the age and body 
mass index (BMI), have shown to be very informative, with regard to the predicting 
miscarriage and stillbirth. The risk of preterm delivery is determined by algorithms 
that combine these results of the first trimester screening for aneuploidy, increased 
nuchal translucency, the abnormal ductus venosus flow, and low level of PAPP-A, 
with the characteristics of the mother [7–9]. Such example is the information on 
the length of the cervical canal from 11- to 13-week gestation [9, 10]. The risk of 
spontaneous preterm delivery is associated with cervical shortening in the second 
trimester, as well as in the first trimester. Combining this parameter with fetal 
aneuploidy analyses and major structural anomaly results is likely to be used in the 
future to select a high-risk group that may benefit from close follow-up.
Another example is the screening for the development of early preeclampsia 
(PE), based on the combination of maternal risk factors, mean arterial pressure, 
maternal serum PAPP-A, uterine artery Doppler, and placental growth factor. This 
algorithm has a 95% detection rate for a false-positive rate of 10% [11, 12]. Also, 
different angiogenesis-related biomarkers; antiangiogenic proteins, like soluble 
fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin; or proangiogenic proteins, 
placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) 
have been pointed out by a number of authors [10]. The placental protein-13 and 
other markers, disintegrin and metalloprotease-12 (ADAM12), activin A, or inhibin 
A, and other microelements or antioxidants, in isolation or in combination, were 
evaluated in order to predict complications of pregnancy [13–15]. It was also shown 
that early administration of low-dose aspirin (60–80 mg), starting from the first 
trimester, reduces the incidence of intrauterine growth restriction as well as its 
related pregnancy and neonatal complications for 17%, with number needed to 
treat (NNT) 72, and 14% reduction in fetal or neonatal deaths with NNT 24 [16].
The detection of the small for gestational age (SGA) fetuses could be predicted 
by algorithms with the combination of maternal characteristics, mean arterial 
pressure, uterine artery Doppler, and the measurement of various placental prod-
ucts in maternal blood at 11–13 weeks, at a false-positive rate of 10%, about 75% of 
pregnancies without preeclampsia delivering SGA neonates before 37 weeks and 
45% of those delivering at term [17]. Screening for macrosomia by a combination 
of maternal characteristics and obstetric history with fetal NT and maternal serum- 
free ß-hCG and PAPP-A at 11–13 weeks could potentially identify, at a false-positive 
rate of 10%, about 35% of women who deliver macrosomic neonates [18].
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Despite the introduction of the vast early pregnancy screening tests, there is 
still a very slight decrease or even increase in the rate of preterm birth and almost a 
constant rate of miscarriage, stillbirth, preeclampsia, and SGA [19–23]. Except for 
hereditary and structural disorders of the fetus, other disorders are etiologically and 
pathophysiologically associated with disturbed placentation and responsible for the 
perinatal mortality and morbidity [24].
The reasons why the modern medicine still fails to significantly improve the 
outcome of pregnancy with the major obstetric syndromes should be sought in the 
earlier period of pregnancy, even before the conception, and on another subcellular 
level (Personal communication Dudenhausen, Tirana 2015). Because the conse-
quence of these disturbances is seen in dysfunctional placentation, their sources 
must be searched before the time of implantation. This means that the changes 
that lead to the insufficient implantation should be sought in the preimplantation 
period, in relation between the embryo and the endometrium.
The onset and progression of pregnancy require the coordinated implanta-
tion of the embryo and trophoblast invasion into the receptive maternal decidua, 
followed by proper remodeling of the spiral arteries. Proliferation, migration, and 
invasion of trophoblastic cells into the maternal endometrium are the essential 
steps. If any of these steps fails to complete properly because of the endometrial 
dysfunction, the consequences would be the basis for development of obstetric 
complications.
3. Maternal health at preconception period
The implanting embryo physically establishes connections with the mother 
through the endometrium, by a fine-tuned and synchronized crosstalk necessary to 
support the feto-placental development and health throughout gestation [25]. Early 
alterations of endometrial physiology can affect the development of the conceptus 
and the success of pregnancy. The overall status of maternal health is reflecting 
on the endometrium. If we agree that the optimally prepared mucous membranes 
(either endogenously, by its own sex hormone or by exogenous regimes) are one 
of the preconditions for the successful implantation, then the modification of its 
preparation could influence the occurrence of disorders in later pregnancy and after 
the birth of the child.
Several studies have shown that preimplantation embryos are sensitive to 
environmental conditions in which it develops, either in vitro or in vivo, for 
example, in response to culture conditions or maternal diet [26]. Those conditions 
can affect future growth and developmental potential, both pre- and postnatally. 
Recent findings have demonstrated that perturbations of the maternal physiol-
ogy during the peri-conceptional period (e.g., maternal diet) have impact both 
on preimplantation phenotype and long-term development and could lead to 
impaired health during adulthood [26]. Emerging evidence suggests the metabolic 
status of the mother may “program” the offspring’s long-term risk of metabolic 
disease [27].
Modifications of preimplantation embryo conditions, using assisted reproduc-
tive technologies (ARTs) or somatic cell nuclear transfer (SCNT), have been associ-
ated with developmental abnormalities and postnatal consequences such as the 
large offspring syndrome (LOS) in animals [28–30]. Early alterations of the mater-
nal or embryo environment may affect the quality of the  embryo-endometrium 
crosstalk that further leads to pregnancy failure or postnatal detrimental 
consequences.
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4. Endometrium
Before the embryo can implant in the endometrium, the endometrium must be 
in a receptive state. As a result of a series of timed hormonal events, the so-called 
window of implantation is opened, which is the time most suitable for the endome-
trium to support trophoblast-endometrial interaction [31].
The term windows of vulnerability (WOV), i.e., period of time when the 
endometrium is subject to the influence of factors that may disrupt implantation 
conditions, has recently been introduced within the framework of reproductive 
medicine, besides the window of implantation (WOI), i.e., the optimal period of 
time of activation of endometrial receptivity (De Ziegler, personal communication, 
MSD symposium, Barcelona 2016).
Prepregnancy approaches such as weight management, blood pressure and 
blood sugar control, smoking cessation, and optimization of the pregnancy 
interval may improve implantation and placentation and lead to better pregnancy 
outcomes [32].
There are a number of different treatment protocols for the “inadequate” 
endometrium. The medical treatment with estrogens, vasodilators, and sildenafil 
citrate has neither led to significant improvements of morphological parameters nor 
to the results in terms of increasing implantation and reduction of the number of 
miscarriages [33, 34]. There have been reports of trials with immunoglobulins and 
anticoagulants in pregnancy complication prevention [35–39].
The local endometrium therapy is ongoing for several years. One of the promis-
ing therapeutic targets is the corticotropin-releasing hormone (CRH). During 
implantation, corticotropin-releasing hormone plays a key role in facilitating 
endometrial decidualization and early maternal tolerance. The embryo implanta-
tion provokes the maternal endometrial response similar to the invading semi-
allograft that produces acute inflammatory response. After the implantation, the 
embryo suppresses this response and prevents the rejection [40]. The deregulation 
of expression pattern of CRH was associated with unfavorable reproductive out-
comes as well as chronic endometrium-derived inflammatory disorders, such as 
endometriosis and adenomyosis [41]. Positive outcome was found after the intra-
uterine administration of autologous peripheral blood mononuclear cells (PBMCs) 
[41] especially when pretreated with corticotropin-releasing hormone that acts 
by regulating apoptosis of activated T- lymphocytes at the implantation site [42]. 
The results of eight studies showed that intrauterine administration of activated 
autologous peripheral blood mononuclear cells prior to embryo transfer improves 
the reproductive outcomes in women with repeated implantation failure [43].
Besides endometrial receptivity, another very important parameter is the 
endometrial thickness. Defined minimal thickness at approximately 7 mm and 
clinical pregnancy rates after embryo transfer increase with increasing endometrial 
thickness. One of the new therapeutic approaches to improve endometrial thickness 
is the intrauterine perfusion with granulocyte colony-stimulating factor (G-CSF). 
In clinical reproduction, G-CSF has been proposed as a treatment for implantation 
failure and repeated miscarriages, two indications for which a US patent has been 
issued. These authors have applied the drug subcutaneously [44]. Gleicher’s papers 
on flushing uterus cavity with growth factors before the embryo transfer have 
proposed granulocyte colony-stimulating factor as the treatment of implantation 
failure and repeated miscarriages [44]. Chang reported successful endometrial 
expansion in a small group of women with thin endometrium resistant to standard 
treatments, who were able to proceed to embryo transfer and conceive after uterine 
perfusion with G-CSF [45].
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The use of platelet-rich plasma (PRP) to improve endometrial receptivity is 
gaining increasing attention in assisted reproduction technologies. Platelets contain 
a significant amount of growth factors that have positive effects on local tissue 
repair and endometrial receptivity. Several authors have reported autologous PRP 
intrauterine injection improves pregnancy and birth rates, especially in patients 
presenting poor endometrial growth [46].
Chang and associates have recently published the attempt to improve the quality 
of endometrial thickness, implantation rate, and pregnancy success and to reduce 
the complications and miscarriage rate, by flushing the uterus cavity with autolo-
gous platelet-rich plasma in preparation for the implantation during IVF process 
[47]. Farimani reported the first successful pregnancy after administration of PRP 
in a woman with recurrent implantation failure [48]. Kim et al. suggested that the 
use of autologous PRP improved not only endometrial thickness but restored the 
endometrial receptivity of damaged endometrium and increased the implantation, 
pregnancy, and live birth rates (LBR) of the 24 patients with refractory thin endo-
metrium [49]. This therapy delivers biological growth factors, PDGF, TGF-b, and 
VEGF, insulin-like growth factor 1, epidermal growth factor (EGF), and epithelial 
cell growth factor to the endometrium. Our group has, so far, treated 25 patients 
with PRP technology and has achieved a significant improvement of the implanta-
tion rates and in reducing the number of abortions. We reported the first case of 
human embryo obtained after autologous platelet leukocyte-rich plasma (PLRP) 
in vitro activation of ovaries by interrupting Hippo signaling and PLRP stimulating 
AKT pathway with ultrasound-guided orthotropic re-transplantation [50]. The 
patient was a case of an early menopausal woman for whom the ovarian cortex was 
frozen, thawed, and treated with autologous PLRP which was then transplanted 
into her menopausal ovaries. Two months after the procedure, follicle formation 
was noted, and an egg was retrieved resulting in a single embryo [50].
The human endometrium is a dynamic tissue that undergoes monthly cyclic 
changes, including proliferation, differentiation, and degeneration. Apoptosis 
is the common pathway of cell death for eliminating senescent endometrial cells 
from the functional layer of the human endometrium during the late secretory 
phases of the cycle. It has recently been implied that autophagy is involved in the 
endometrial cell cycle affecting apoptosis and is the most prominent during the 
late secretory phase [51]. It is known that the impact on autophagy processes in 
the endometrium may lead to a reduced incidence of pregnancy complications 
related to the implantation. Our group has proved that autophagy, a process of 
controlled self-digestion involved in cellular homeostasis, is dysregulated in endo-
metrial tissue of polycystic ovary syndrome (PCOS) patients and that treatment 
with metformin might influence endometrial autophagy in PCOS [52]. Other 
studies reported that metformin can improve endometrial receptivity, enhance 
endometrial vascularity and blood flow, and revert endometrial hyperplasia and 
carcinoma into normal endometria in addition to improving hyperandrogenism 
and insulin resistance in some women with PCOS [53, 54].
5. Embryo environment
The essential requirements for normal implantation and subsequent pla-
centation leading to a healthy gestation are receptive endometrium and healthy 
embryo. However, there is still a growing number of unexplained failed implanta-
tion outcomes that could not be assigned to known factors and require further 
investigation.
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In recent years it was indicated that different etiologies of infertility arose 
as a result of the underlying genetic and epigenetic changes that contribute to 
the endometrial dysfunction and lead to implantation failure, miscarriage, and 
adverse outcomes. These epigenetic and genetic changes lead to placentation 
defects and contribute to the short- and long-term outcomes associated with 
infertility. One of the main causes for altered genetic and epigenetic regula-
tion of embryo development and placentation was assigned to hormonal and 
nutrition-related changes in maternal environment. Embryos respond to the 
in vivo maternal environment during gestation or during cultivation in vitro in 
multiple ways that can influence their future growth and health. Developmental 
plasticity could be altered by the changes in imprinted gene expression, nutrient, 
and stress-related signaling pathways or cell cycling and apoptotic rates. Embryo 
phenotype changes through a complex network of interactions with a central 
role for maternal-fetal neuroendocrine signaling [55]. Maternal undernutrition 
during gestation alters maternal steroid hormone levels, including elevation of 
glucocorticoids (GC; corticosterone, cortisol), the stress hormones, which can 
alter the physiological condition of the conceptus and affect the intrauterine fetal 
and postnatal growth and cardiovascular and metabolic physiology and enhance 
the risk of adult-onset disease. This exposure of the embryo to glucocorticoids can 
alter the fetal hypothalamus pituitary adrenal (HPA) axis, leading to increased 
fetal GC activity which can, in turn, modify the expression of many downstream-
regulated genes that control growth and metabolism, including cardiovascular 
and renal physiology [55].
The influence of placental function and placental/fetal exchange on fetal 
programming has been in focus of the recent research. Now it has become widely 
accepted that maternal nutrition can have the long-term consequences on the 
offspring without necessarily affecting the size at birth. Altered embryo pheno-
types induced by prenatal nutrition are associated with epigenetic modifications. 
Many imprinted genes contribute to placental function and nutrient exchange [56]. 
Early epigenetic effects in embryos caused by environmental conditions can lead to 
physiological impairment to growth due to reduced nutrient supply. There is now 
evidence from human studies and animal experiments that show the overnutrition 
and undernutrition during the prenatal period which have lifelong health effects 
for the offspring and induce the development of noncommunicable diseases during 
postnatal life [57].
Besides nutrition, the hormonal milieu at conception is known to affect a 
number of imprinted genes that are expressed during the preimplantation period. 
Hormonal status will be especially affected during fertility treatment, mostly dur-
ing IVF.  Because superovulation could lead to altered expression of endometrial 
genes critical to tissue remodeling and placentation, hyperstimulated hormonal 
status has been implicated in an increased risk for pregnancy complications related 
to abnormal placentation [58]. Although global methylation pattern was found to 
be similar among the IVF and spontaneous conceptions early during placentation 
in the first trimester, differential methylation has been identified in multiple loci 
between IVF and non-IVF fertility treatments pregnancies but not when com-
pared with spontaneous conceptions. This suggests that there are differences in 
the infertile population that might be linked to specific treatments, including the 
hormonal hyperstimulation, that could affect gene imprinting [59]. Several studies 
have found that the use of ARTs is linked with irregular DNA methylation in 
human gamete, embryo, placenta, and umbilical cord samples [60, 61]. There were 
also studies that showed association between specific procedures with methyla-
tion differences in placenta, suggesting that specific fertility treatments affect the 
placental epigenome and function [62].
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6. Embryo monitoring
The embryo has, in addition to the endometrium, the crucial importance for 
the success and regularity of the implantation and then placentation. The mor-
phological assessment of the embryos’ quality is insufficient for the cognition of 
its biological resources. The new invasive and noninvasive techniques of embryo 
quality assessment have been developed. Nowadays, the invasive technology means 
preimplantation genetic testing (PGT), the aneuploidy screening, or diagnosis 
of specific genetic disorders of the embryo before the transfer by using next-
generation sequencing (NGS). These tests include biopsy trophectoderm cells with 
blastocyst vitrification [63–65]. With trophectoderm biopsy, both maternal and 
paternal abnormalities can be studied. Possible disadvantages are the presence of 
mosaicism and the fact that the trophectoderm might not be a representative of the 
inner cell mass.
Noninvasive time-lapse embryo monitoring allows continuous embryo observa-
tion without the need to remove the embryo from optimal culturing conditions. The 
information on the cleavage pattern, morphologic changes, and embryo develop-
ment dynamics could help us identify embryos with a higher implantation poten-
tial. It has also been shown that imaging phenotypes reflect the molecular program 
of the embryo, where individual blastomeres develop autonomously toward embryo 
genomic activation [66].
This type of monitoring allows for the collection of much more information on 
the timing of the cleavages and the dynamics of the morphologic changes, with 
analysis of the kinetics of the events up until the blastocyst stage [67].
Various kinetic and morphologic markers have already been found that are 
associated with the minimal likelihood of implantation and others that are pre-
dictive of blastocyst development, implantation potential, genetic health, and 
 pregnancy [68, 69].
7. Gametes
After the formation of the embryo, its fate is already determined. The gamete 
quality has the crucial part in the creation of the high-quality embryos. The condi-
tions, in which oogenesis and spermatogenesis take place, have a crucial impact on 
the quality of embryos that is formed from these gametes.
7.1 Oogenesis
The evaluation of the oocyte quality based on morphological evaluation is not 
sufficient for an insight into the biological potential. It can identify those cells 
that have nuclear immaturity, significant degeneration, or major abnormalities. 
Recently, the developed strategies including the genomic, transcriptomic, and 
proteomic approaches have been applied in assisted reproduction. Their goal is to 
identify a “molecular profile” of embryo development by detecting the chemical 
components in the oocyte, granulosa cells, follicular fluid, and embryo culture 
medium [70].
Better predictors, the birefringence properties of the meiotic spindle, and the 
zona pellucida are indicative of good health of the oocyte [71]. A very useful data 
can be obtained from the application of studying gene expression from cumulus 
cells, using microarrays, as biomarkers for oocyte viability. The metabolomic 
profiling of oocyte spent culture media by mass spectroscopy has shown dif-
ferences related to oocyte maturation, embryo development, and implantation 
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success [72]. Oocyte quality can be assessed by the measurement of oocyte 
oxygen consumption [73].
Spermatogenesis: the quality of spermatogenesis is the condition for the forma-
tion of a good embryo. The advanced sperm selection techniques are based not 
only on the morphological assessment (defragmentation, MACS) but also on the 
evaluation of specific cellular characteristics (membrane integrity, density, surface 
charge) that provide a choice of better quality sperm. The methods of improving 
conditions of gametogenesis, which are applied so far, do not provide a sufficient 
effect. They are mainly related to the balance correction of microelements and 
vitamins, as well as the oxydo-reductive processes in the body. The sperm chroma-
tin and DNA integrity are necessary to ensure normal embryo development. It is 
now clear that DNA damage in spermatozoa has a negative influence on blastocyst 
development and the pregnancy outcome [74] . Similarly, centrosome integrity is 
critical for successful fertilization and embryo development. There are studies that 
have described the association between sperm with DNA damage and a history of 
recurrent miscarriage [75].
7.2 Advanced therapy
Magnetic-activated cell sorting (MACS) technology for sperm could improve 
obstetric and perinatal outcomes compared with those achieved after swim 
up. Treatment of sperm with MACS procedure prior to IVF results in a marked 
improvement in pregnancy rate and cessation of the abortion rate in couples whose 
ejaculates initially had high levels of SDF [76].
A number of prerequisites are needed to create high-quality oocytes, those condi-
tions are likely to be grouped into several parts: the existence of high quality responsive 
oogonia, its potential of the adequate number increase and quality of mitochondria, 
the presence of sufficient amounts and types of growth factors, orchestrated by the 
balance of blocking (Hippo) and activating (ACT) gene pathways [77].
For decades it was believed that the woman’s reproductive potential is entirely 
dependent on the size of the stock (pool) of primordial follicles in the ovary. The 
paradigm that has prevailed for decades in the scientific world about the existence 
of a consistent number of primordial follicles, established during embryonic and 
fetal period, was in many ways changed by Tilly’s group work. They practically 
demonstrated the existence of germline or oogonial stem cells [78].
Their dormant status is characterized by communication with surrounding 
granulosa cells and numerous mechanical and chemical factors controlling the 
progression of their cell cycle. These factors control signaling activation of the 
pathways included in the primordial follicle dormant status regulation, like Hippo 
and AKT signaling [77]. During the recent years, various programs have been 
developed to try to improve the quality of oocytes. It has been shown that it can 
be influenced on the activation of primordial cells and maturation to the mature 
oocyte. The stem cells can be influenced by the stem cell therapy in order to obtain 
the intracellular communication with the existing ovarian primordial oogonia. The 
therapy with mesenchymal stem cells has led to the recovery features of oocytes 
after the chemotherapy-induced insufficiency [79]. The animal experiments by 
the in vitro therapy with developed stem cells have led to the birth of live offspring 
without abnormalities [80]. Other groups of authors have tried to improve the ovar-
ian function with the growth factors obtained from the plasma and enriched with 
platelets and leukocytes. The cases of childbirth after re-transplantation of ovaries 
with support of PRP have been published [81]. Our group has achieved a normal 
pregnancy outcome after the sonographically guided therapy with growth factors in 
a female patient aged 40 years, after 18 attempts of in vitro fertilization.
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The role of the number and function of mitochondria in the development of 
quality oocytes is surely very important. The problems of mitochondrial hetero-
plasmy go with the complicated, technologically very complex methods of polar 
body transfer, spindle transfer, and pronuclear or oocyte transfer [82–84]. The 
augmentation of autologous mitochondria carries a potential treatment. Our team 
has inaugurated the attempt of the mitochondrial energy boosting with ovarian 
high-intensity interval training (HIIT).
The autologous growth factors that are intraovarian instilled are leading to the 
changes in the production and efficiency of the local growth factors. The influence 
on the genetic control of oogenesis, by the modification of the Hippo and AKT sig-
naling pathways, is possible in different ways. The correction of the gene signaling 
or autologous tissue genetic bioengineering is certainly a step forward in obtaining 
the quality gametes [50, 84].
8. Conclusion
Implantation is one of the crucial periods in human reproduction. Increasing 
body of evidence suggests that the improper (dysfunctional) implantation and the 
formation of the placenta can endanger life and health of both the fetus and the 
mother, during prenatal life and decades after delivery. The changes that lead to 
the insufficient implantation should be sought in the preimplantation period, in 
relation between the embryo and the endometrium. It is possible that the time is 
approaching when the disorders of the pregnancy caused by dysfunctional implan-
tation would be the indication for the application of a natural IVF (without ovarian 
stimulation) with the use of new biotechnological achievements. For better results 
of the perinatal medicine, it is necessary to apply earlier (in the preconception and 
preimplantation periods) the therapy based on the subcellular and genetic level by 
applying the latest biotechnological procedures.
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